Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)-Reference-Cited by-同舟云学术

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)

Published:2019-01 Issue:1 Volume:14 Page:115-123
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Früh Martin,Betticher Daniel C.,Stupp Roger,Xyrafas Alexandros,Peters Solange,Ris Hans Beat,Mirimanoff Rene Olivier,Ochsenbein Adrian F.,Schmid Ralph,Matzinger Oscar,Stahel Rolf A.,Weder Walter,Guckenberger Matthias,Rothschild Sacha I.,Lardinois Didier,Mach Nicholas,Mark Michael,Gautschi Oliver,Thierstein Sandra,Biaggi Rudolf Christine,Pless Miklos

Funder

Swiss Cancer League and the Swiss State Secretariat for Education, Research and Innovation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. TNM Classification of Malignant Tumours,2016

2. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)

3. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non–small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial;Früh;Ann Oncol,2016

4. Induction chemoradiation in stage IIIA2/N2 non–small-cell lung cancer: a phase 3 randomised trial;Pless;Lancet,2015

5. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a multicenter phase II trial;Betticher;J Clin Oncol,2003

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer (ESPATUE);International Journal of Cancer;2024-08-28

2. Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection;Cancers;2024-08-20

3. The impact of serum sodium levels on short and long-term outcomes after lung resection for non-small cell lung cancer: a retrospective cohort study;Current Challenges in Thoracic Surgery;2024-04

4. Survivorship Program Including Long-Term Toxicities and Quality-of-Life Development Over Ten Years within a Randomized Phase-III Trial in Operable Stage III Non-Small-Cell Lung Cancer (ESPATUE);2023-12-11

5. Predictive Value of Blood Biomarkers in Elderly Patients With Non-Small-Cell Lung Cancer;Biomarkers in Medicine;2023-12